Analystreport

Adaptimmune Therapeutics (NASDAQ: ADAP) had its price target raised by analysts at SunTrust Banks to $18.00. They now have a "buy" rating on the stock.

Adaptimmune Therapeutics plc - American Depositary Shares  (ADAP) 
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am Check Earnings Report